Pharma: Clinic Roundup
Friday, April 27, 2012
Shire plc, of Dublin, Ireland, said its Phase II trial of Vyvanse (lisdexamfetamine dimesylate) for adults with binge-eating disorder met its primary endpoint of significantly reducing the number of binge days per week at the two highest of three doses tested.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.